Want to see HAE full AI Analyst Report?
HAE Stock Chart & Stats
$78.78
$1.13(1.43%)
At close: 4:00 PM EDT
$78.78
$1.13(1.43%)
Day’s Range― - ―
52-Week Range$47.32 - $109.57
Previous Close$79.91
Volume803.18K
Average Volume (3M)720.82K
Market Cap
$4.92B
Enterprise Value$4.48K
Total Cash (Recent Filing)$223.38M
Total Debt (Recent Filing)$1.17B
Price to Earnings (P/E)52.8
Beta0.44
Next Earnings
Nov 05, 2026EPS Estimate
1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.06
Shares Outstanding45,497,050
10 Day Avg. Volume569,544
30 Day Avg. Volume720,821
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)3.20
Price to Sales (P/S)1.91
P/FCF Ratio9.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$102.38Price Target Upside29.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)5.29
Revenue Forecast (FY)$1.41B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelHaemonetics benefits from an installed-base model in which adopted collection and hospital systems drive repeat consumables, service and software revenue. This creates customer stickiness, improves revenue visibility and supports durable cash generation.
CSL Plasma ExpansionThe non-exclusive CSL agreement could expand Haemonetics’ plasma equipment footprint and create additional recurring disposable demand. Although timing and scope are undecided, the relationship supports longer-term penetration in a strategically important market.
Growth And Cash GenerationRaised fiscal guidance, broad-based platform growth and strong operating cash flow indicate healthy demand and effective cash conversion. Management’s ability to generate free cash flow while funding operations provides resources for debt reduction and ongoing product investment.
Bears Say
Elevated LeverageHigher leverage reduces financial flexibility compared with prior years and increases sensitivity to weaker earnings, interest costs or slower customer demand. Deleveraging is underway, but debt remains a meaningful constraint on resilience and capital allocation.
Margin And Cost PressureMargin compression alongside higher personnel, acquisition and freight costs could limit operating leverage if inflationary pressures persist. Sustaining profitability will require successful cost control and favorable mix, particularly as external costs remain difficult to predict.
Uneven Segment ExecutionWeakness in non-plasma Apheresis and parts of IVT shows that growth is not uniform across the portfolio. Continued softness could make results more dependent on plasma and vascular-closure momentum, increasing execution and product-mix risk.
Haemonetics News
HAE FAQ
What was Haemonetics’s price range in the past 12 months?
Haemonetics lowest stock price was $47.31 and its highest was $109.57 in the past 12 months.
What is Haemonetics’s market cap?
Haemonetics’s market cap is $4.92B.
When is Haemonetics’s upcoming earnings report date?
Haemonetics’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Haemonetics’s earnings last quarter?
Haemonetics released its earnings results on Aug 06, 2026. The company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $1.077 by $0.063.
Is Haemonetics overvalued?
According to Wall Street analysts Haemonetics’s price is currently Undervalued.
Does Haemonetics pay dividends?
Haemonetics does not currently pay dividends.
What is Haemonetics’s EPS estimate?
Haemonetics’s EPS estimate is 1.29.
How many shares outstanding does Haemonetics have?
Haemonetics has 45,497,050 shares outstanding.
What happened to Haemonetics’s price movement after its last earnings report?
Haemonetics reported an EPS of $1.14 in its last earnings report, beating expectations of $1.077. Following the earnings report the stock price went up 1.699%.
Which hedge fund is a major shareholder of Haemonetics?
Currently, no hedge funds are holding shares in HAE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haemonetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$102.38 (29.95% Upside)
$102.38 (29.95% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.2%
Last 30 Days ▲ 17.7%
Last 30 Days ▲ 17.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.24%
Trailing 12-Months
Company Description
Haemonetics
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
HAE Company Deck
HAE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated broad‑based operational momentum: solid revenue and EPS growth, strong performance across core platforms (notably Plasma/Persona PLUS, Hemostasis, and Vascular Closure), upgraded fiscal guidance, and exceptional cash generation and debt paydown activity. Offsetting items include near‑term margin compression from prior‑year software recognition and sequential MedSurg revenue timing, higher operating costs, some OEM/ensoETM weakness in IVT, and continued external inflation/FX/headwind risks. Management emphasized disciplined, conservative guidance and prioritized deleveraging while keeping optionality for share repurchases and organic investment.View all HAE earnings summariesHAE Stock 12 Month Forecast
Average Price Target
$102.38
▲(29.95% Upside)
Technical Analysis
Ownership Overview
1.82% Insiders
38.40% Mutual Funds
24.14% Other Institutional Investors
7.34% Public Companies and
Individual Investors